Production And Purification Of Adeno-Associated Virus At The 50 L Scale

This study demonstrates the ability of the CTS AAV-MAX production system to scale up to 50 L in DynaDrive S.U.B.s producing AAV6 anti-CD19 chimeric antigen receptor (AAV6-CD19CAR). Robust scalability of the AAV-MAX system allows for streamlined use of the system from research through clinical and commercial manufacturing, enabling gene therapy researchers to utilize one system throughout their entire development process.

Explore data on the production, purification, and characterization of an AAV6-CD19CAR in the DynaDrive S.U.B. at the 50 L scale.